AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 278: E1053-E1059, 2000;
0193-1849/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bøtker, H. E.
Right arrow Articles by Schmitz, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bøtker, H. E.
Right arrow Articles by Schmitz, O.
Vol. 278, Issue 6, E1053-E1059, June 2000

Short-term effects of growth hormone on myocardial glucose uptake in healthy humans

Hans Erik Bøtker1, Henrik Wiggers1, Morten Bøttcher1, Jens Sandahl Christiansen2, Torsten Toftegaard Nielsen1, Albert Gjedde3, and Ole Schmitz2

1 Department of Cardiology, Skejby Hospital, University Hospital in Aarhus, DK-8200 Aarhus N; and 2 Department of Medicine M (Endocrinology and Diabetes) and 3 The PET Centre, Aarhus Kommunehospital, University Hospital in Aarhus, DK-8000 Aarhus C, Denmark

Cardiac muscle is characterized by insulin resistance in specific heart diseases such as coronary artery disease and congestive heart failure, but not in generalized disorders like diabetes mellitus and essential hypertension when cardiac manifestations are absent. To examine whether the insulin antagonistic effect of growth hormone (GH) acts upon the heart, we compared insulin-stimulated whole body and myocardial glucose uptake with and without GH administration during a 3.5-h euglycemic-hyperinsulinemic clamp in eight healthy males. Myocardial 2-deoxy-2-[18F]fluoro-D-glucose uptake was measured with positron emission tomography. The data were converted to myocardial glucose uptake by tracer kinetic analysis. GH did not change the rate-pressure product. GH decreased whole body insulin-stimulated glucose disposal by 26% (48.0 ± 12.1 vs. control 62.8 ± 6.1 µmol · kg-1 · min-1, P < 0.02). Free fatty acids were suppressed to a similar extent with and without GH during the insulin clamp. Insulin-stimulated myocardial glucose uptake was similar in the presence and in the absence of GH (0.34 ± 0.05 and 0.31 ± 0.03 µmol · g-1 · min-1, P = 0.18). In conclusion, GH does not impair insulin-stimulated myocardial glucose uptake despite a considerable whole body insulin antagonistic effect. Myocardial insulin resistance is not an inherent consequence of whole body insulin resistance.

insulin resistance; heart; metabolism; heart failure; positron emission tomography


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. Jessen, C. B. Djurhuus, J. O. L. Jorgensen, L. S. Jensen, N. Moller, S. Lund, and O. Schmitz
Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E194 - E199.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online